My Reports
RGCIRC, Niti Bagh
Ewing’s Sarcoma Treatment
Ewing’s sarcoma is a rare and aggressive bone and soft tissue cancer that primarily affects children, adolescents, and young adults, requiring timely diagnosis and carefully coordinated multi-modality treatment. At RGCIRC (Rajiv Gandhi Cancer Institute & Research Centre), Ewing’s sarcoma treatment is delivered through an integrated cancer care framework that combines advanced diagnostics, systemic therapy, local tumour control, and structured rehabilitation. Treatment plans are individualised based on tumour location, stage, and response to therapy, ensuring that care is both precise and balanced. With dedicated expertise across medical oncology, orthopaedic oncology, radiation oncology, and supportive services, RGCIRC provides end-to-end care for Ewing’s sarcoma, focusing not only on disease control but also on functional recovery, long-term wellbeing, and continuity of care beyond treatment.
Understanding Ewing’s Sarcoma
Ewing’s sarcoma is a type of cancer that develops from cells in the bone or surrounding soft tissue. It belongs to a group of tumours known as the Ewing sarcoma family and is characterised by abnormal cell growth driven by specific genetic changes within the tumour cells.
The disease most commonly affects the bones of the pelvis, thigh (femur), lower leg (tibia), upper arm (humerus), and chest wall, though it can also arise in soft tissues outside the bone (extra-osseous Ewing’s sarcoma). The location of the tumour often influences symptoms, treatment planning, and functional outcomes.
Ewing’s sarcoma is seen predominantly in children, adolescents, and young adults, and is uncommon in older age groups. Because it can grow and spread quickly, early recognition and prompt specialist evaluation are essential for effective treatment planning and improved outcomes.
Types and Patterns of Ewing’s Sarcoma
Ewing’s sarcoma can present in different forms depending on where the tumour originates and whether it has spread at the time of diagnosis. Understanding these patterns helps guide treatment planning and expectations.
The main types and patterns include:
- Skeletal (bone) Ewing’s sarcoma: The most common form, arising within the bone. It frequently affects the pelvis, long bones of the arms and legs, or the chest wall.
- Extra-osseous (soft tissue) Ewing’s sarcoma: A less common form that develops in soft tissues around the bone rather than within the bone itself. Treatment principles are similar but surgical planning may differ based on location.
- Localised Ewing’s sarcoma: The cancer is confined to the area where it started. Localised disease generally has better outcomes when treated with a combination of chemotherapy and local control measures.
- Metastatic Ewing’s sarcoma: The cancer has spread to other parts of the body, most commonly the lungs, other bones, or bone marrow. Metastatic disease requires more intensive, carefully planned treatment.
Identifying the type and pattern of Ewing’s sarcoma allows treatment to be tailored appropriately, balancing effective disease control with preservation of function and long-term quality of life.
Causes and Risk Factors for Ewing’s Sarcoma
The exact cause of Ewing’s sarcoma is not fully understood. The disease develops due to a specific genetic change within tumour cells that leads to uncontrolled growth. This genetic alteration occurs spontaneously and is not inherited, meaning it is not passed down from parents to children.
Key points to understand about risk factors include:
- Genetic translocation within tumour cells: Ewing’s sarcoma is associated with a characteristic change in genetic material that drives tumour growth. This change develops during a person’s lifetime and is not related to family history.
- Age-related occurrence: The condition is most commonly diagnosed in children, adolescents, and young adults, though the reason for this age distribution is not clearly established.
- No known lifestyle or environmental risk factors: Unlike some cancers, Ewing’s sarcoma has not been linked to diet, physical activity, infections, or environmental exposures.
In most cases, there are no identifiable risk factors, and nothing a patient or family did caused the disease. Because symptoms can be non-specific in the early stages, timely specialist evaluation remains the most important factor in achieving early diagnosis and effective treatment.
Signs, Symptoms, and When to See a Specialist
The symptoms of Ewing’s sarcoma often begin subtly and may resemble common injuries or infections, particularly in children and adolescents. However, unlike routine conditions, these symptoms tend to persist or progressively worsen, making early specialist evaluation important.
Common signs and symptoms include:
- Persistent bone pain: Pain that does not improve with rest and may worsen at night or with activity
- Swelling or a noticeable lump: Around the affected bone or soft tissue, which may increase in size over time
- Limping or reduced movement: Especially when the tumour affects weight-bearing bones such as the pelvis or leg
- Fever, fatigue, or unexplained weight loss: In some cases, reflecting the body’s response to the disease
- Tenderness or warmth over the affected area: Particularly with soft tissue involvement
A specialist consultation is recommended if bone pain or swelling persists for several weeks, worsens over time, or is associated with functional limitation such as limping or restricted movement.
How is Ewing’s Sarcoma Diagnosed?
Diagnosing Ewing’s sarcoma requires a structured evaluation to confirm the disease, determine its extent, and plan appropriate treatment. Because this cancer can grow and spread rapidly, investigations are carried out promptly at specialised centres.
The diagnostic process typically includes:
- Imaging Studies: An X-ray is often the first investigation and may show changes in the affected bone. MRI is used to assess the size of the tumour, involvement of surrounding tissues, and relationship to nearby nerves and joints. CT scans may be performed to evaluate bone detail and check for spread, particularly to the lungs.
- Biopsy: A biopsy is essential to confirm the diagnosis. A small sample of tumour tissue is examined under a microscope to identify Ewing’s sarcoma. Biopsy planning is done carefully to avoid interfering with future surgical options.
- Molecular and Genetic Testing: Specialised tests are used to detect characteristic genetic changes associated with Ewing’s sarcoma, which help confirm the diagnosis and guide treatment planning.
- Staging Investigations: Additional tests, including scans and, in some cases, bone marrow examination, are performed to assess whether the cancer has spread to other parts of the body.
Once all investigations are complete, the findings are reviewed by a multidisciplinary team to determine the most appropriate treatment strategy for each patient.
Understanding Stage and Prognosis in Ewing’s Sarcoma
After Ewing’s sarcoma is diagnosed, the next step is to determine the stage of the disease and assess factors that influence prognosis. This evaluation helps guide treatment intensity and provides a clearer understanding of expected outcomes.
Ewing’s sarcoma is broadly classified as:
- Localised Disease: The cancer is confined to the bone or soft tissue where it started, without evidence of spread. Localised Ewing’s sarcoma generally has better outcomes when treated with a combination of chemotherapy and effective local control.
- Metastatic Disease: The cancer has spread to other parts of the body, most commonly the lungs, other bones, or bone marrow. Metastatic disease requires more intensive, carefully planned treatment and closer long-term monitoring.
Prognosis in Ewing’s sarcoma is influenced by several factors, including:
- Tumour location and size
- Extent of disease at diagnosis
- Response to initial chemotherapy
- Overall health and age of the patient
Advances in multimodal treatment have significantly improved outcomes, particularly for patients with localised disease. Accurate staging and early treatment planning allow therapy to be tailored appropriately, balancing effective cancer control with long-term function and quality of life.
Treatment Options for Ewing’s Sarcoma at RGCIRC, Delhi
Treatment for Ewing’s sarcoma at RGCIRC follows a multimodal, risk-adapted approach, combining systemic therapy with local tumour control. Treatment plans are individualised based on tumour location, stage, response to chemotherapy, and functional considerations.
Key components of treatment include:
- Chemotherapy: Chemotherapy forms the backbone of Ewing’s sarcoma treatment and is typically given both before and after local therapy. Pre-treatment chemotherapy helps shrink the tumour, address microscopic disease, and assess response, while post-treatment chemotherapy reduces the risk of recurrence.
- Surgery: Surgical removal of the tumour is planned whenever feasible, with a strong emphasis on limb-sparing procedures and preservation of function. Surgical strategy depends on tumour size, location, and response to chemotherapy, and is planned carefully to achieve effective local control.
- Radiation therapy: Radiation therapy may be used when surgery is not possible, when complete surgical removal cannot be achieved, or as part of combined local control in selected cases. Advanced radiation techniques are used to minimise exposure to surrounding healthy tissue.
Treatment decisions at RGCIRC are made through multidisciplinary planning involving medical oncology, orthopaedic oncology, radiation oncology, imaging, and rehabilitation teams, ensuring care is comprehensive, coordinated, and aligned with long-term outcomes.
Possible Complications During Ewing’s Sarcoma Treatment
Anticipating these risks and managing them proactively is an essential part of specialised care, particularly in children and young adults.
Possible complications during treatment may include:
- Chemotherapy-related side effects: Fatigue, nausea, temporary hair loss, lowered immunity, and an increased risk of infections, requiring close monitoring and supportive care
- Surgical complications: Risks related to wound healing, infection, or impact on surrounding muscles, nerves, and joints, especially in limb-sparing procedures
- Radiation-related effects: Temporary skin changes, fatigue, or effects on nearby tissues, depending on the treatment site
- Functional and mobility challenges: Short-term or long-term limitations in movement or strength that may require structured rehabilitation
- Emotional and psychological impact: Anxiety, stress, and adjustment difficulties for patients and families during prolonged treatment
With coordinated multidisciplinary care and integrated supportive services, most treatment-related complications can be effectively managed, allowing patients to continue therapy safely and focus on recovery.
Supportive and Rehabilitation Care
Supportive and rehabilitation care is an integral part of Ewing’s sarcoma treatment, particularly given the intensity of chemotherapy and the functional impact of surgery or radiation therapy. Alongside cancer-directed treatment, focused supportive care helps patients tolerate therapy better, recover safely, and regain physical function.
Supportive and rehabilitation care includes:
- Pain and symptom management: Careful control of pain, swelling, nausea, and treatment-related discomfort to improve comfort and day-to-day functioning
- Physiotherapy and functional rehabilitation: Structured programmes to restore strength, mobility, balance, and range of motion, especially after limb surgery or radiation therapy
- Nutritional support: Individualised dietary guidance to maintain strength, support healing, and manage appetite or weight changes during treatment
- Psychological and emotional support: Counselling and support services for patients and families to help manage anxiety, stress, and the emotional impact of prolonged treatment
- Long-term functional support: Ongoing assessment to address movement limitations, school or work reintegration, and quality-of-life concerns
Early integration of rehabilitation and supportive care helps optimise recovery and supports patients in returning to daily activities with greater confidence.
Life After Ewing’s Sarcoma Treatment and Follow-Up
Completion of treatment for Ewing’s sarcoma marks an important phase in recovery, but long-term follow-up care remains essential. Regular monitoring helps ensure that the disease remains under control, supports physical recovery, and allows early identification of any late effects related to treatment.
Post-treatment follow-up typically includes:
- Regular clinical reviews and imaging: Scheduled visits and scans to monitor for recurrence and assess healing at the treated site
- Monitoring for late effects: Ongoing assessment of growth, bone health, organ function, and overall wellbeing, particularly in children and adolescents who have received intensive therapy
- Continued rehabilitation: Physiotherapy and functional support to improve strength, mobility, and endurance over time
- Psychosocial support: Guidance to help patients and families adjust after treatment and address emotional or educational challenges
A structured follow-up plan supports long-term health, functional independence, and quality of life, helping patients move forward with confidence after Ewing’s sarcoma treatment.
Why Choose RGCIRC for Ewing’s Sarcoma Treatment in Delhi
Ewing’s sarcoma requires highly specialised care that brings together advanced diagnostics, intensive chemotherapy, precise local tumour control, and long-term rehabilitation. At RGCIRC, patients benefit from an ecosystem built exclusively for complex cancer care, supported by decades of institutional expertise and continuous innovation.
Key strengths that distinguish Ewing’s sarcoma care at RGCIRC include:
- Exclusive focus on oncology with deep clinical expertise: RGCIRC is one of Asia’s leading dedicated cancer centres, with specialised teams experienced in managing rare and aggressive cancers such as Ewing’s sarcoma. Care is delivered by medical, surgical, and radiation oncologists who routinely treat complex sarcoma cases across age groups.
- Multidisciplinary tumour board–driven decision-making: Every case is reviewed through structured multidisciplinary tumour boards, bringing together oncologists, orthopaedic surgeons, radiologists, pathologists, and rehabilitation specialists to determine the most appropriate, evidence-based treatment strategy.
- Advanced diagnostic and molecular capabilities: The institute is equipped with comprehensive imaging, molecular diagnostics, next-generation sequencing, liquid biopsy, and tumour biology assessment facilities, enabling accurate diagnosis, staging, and treatment planning for sarcomas.
- Comprehensive treatment infrastructure under one roof: From intensive chemotherapy delivery and limb-sparing surgery to precision radiation techniques and nuclear medicine, RGCIRC offers end-to-end cancer treatment without fragmentation of care. Dedicated operation theatres, critical care services, and transfusion support enable safe delivery of intensive therapy.
- Strong emphasis on research-driven oncology care: RGCIRC actively integrates evolving global evidence into clinical practice, supported by its biorepository, research programmes, academic training, and long-term outcome tracking. This research-oriented approach is particularly critical for rare cancers such as Ewing’s sarcoma, where treatment protocols continue to evolve.
- Integrated supportive and rehabilitation services: Physiotherapy, psycho-oncology, nutrition, pain management, and long-term rehabilitation are embedded into the treatment pathway, ensuring that recovery, function, and quality of life are addressed alongside cancer control.
- Recognised excellence and national leadership: With multiple national and international accreditations, global recognitions by Newsweek, and a long history of trusted cancer care, RGCIRC stands out as a centre known for clinical credibility, ethical practice, and patient-focused oncology.
By combining specialised expertise, advanced technology, research-driven care, and comprehensive support services, RGCIRC offers a level of sarcoma care designed not only to treat Ewing’s sarcoma effectively, but to support patients and families through every stage of the journey.
Next Steps in Ewing’s Sarcoma Care
A diagnosis of Ewing’s sarcoma can be overwhelming for patients and families, but timely access to specialised care plays a critical role in improving outcomes. Advances in chemotherapy, surgical techniques, radiation therapy, and supportive care have made it possible to treat this rare cancer with greater precision and long-term disease control.
To consult a cancer specialist for Ewing’s sarcoma evaluation, treatment, or a second opinion at RGCIRC, simply call +91-11-47022222, +91 11 27051037
Frequently Asked Questions
What is Ewing’s sarcoma and who does it affect?
Ewing’s sarcoma is a rare cancer that develops in the bones or surrounding soft tissues. It most commonly affects children, adolescents, and young adults, though it can also occur in adults.
Is Ewing’s sarcoma curable?
Yes. When diagnosed at an early, localised stage, Ewing’s sarcoma can be treated effectively with a combination of chemotherapy and local tumour control. Outcomes depend on factors such as stage at diagnosis and response to treatment.
What are the early signs of Ewing’s sarcoma in children?
Early signs may include persistent bone pain, swelling at the affected site, limping, or reduced use of a limb. These symptoms often worsen over time rather than improving with rest.
How is Ewing’s sarcoma diagnosed?
Diagnosis involves imaging tests such as X-rays and MRI, followed by a biopsy to confirm the disease. Molecular testing is also used to identify characteristic genetic changes associated with Ewing’s sarcoma.
What are the stages of Ewing’s sarcoma?
Ewing’s sarcoma is broadly classified as localised (confined to the original site) or metastatic (spread to other parts of the body such as the lungs, bones, or bone marrow).
What treatment options are available for Ewing’s sarcoma?
Treatment usually involves a combination of chemotherapy, surgery, and radiation therapy. The exact plan is tailored based on tumour location, stage, and response to initial treatment.
Is surgery always required for Ewing’s sarcoma?
Not always. Surgery is preferred when the tumour can be removed safely, but radiation therapy may be used when surgery is not feasible or as part of combined local control.
What is the role of chemotherapy in Ewing’s sarcoma treatment?
Chemotherapy is a core component of treatment and is typically given both before and after local therapy. It helps shrink the tumour, treat microscopic disease, and reduce the risk of recurrence.
Can Ewing’s sarcoma recur after treatment?
Recurrence is possible, particularly within the first few years after treatment. This is why structured follow-up and regular monitoring are essential after completion of therapy.
What is the survival rate of Ewing’s sarcoma?
Survival outcomes vary depending on disease stage, tumour location, and response to treatment. Patients with localised disease generally have better outcomes than those with metastatic disease.
Does Ewing’s sarcoma affect adults differently than children?
The disease biology is similar, but treatment tolerance, recovery, and outcomes may vary between children and adults. Treatment planning takes age and overall health into account.
What are the side effects of Ewing’s sarcoma treatment?
Side effects depend on the treatments used and may include fatigue, nausea, hair loss, lowered immunity, or temporary functional limitations. Supportive care helps manage these effects effectively.
How long does Ewing’s sarcoma treatment take?
Treatment typically extends over several months and includes multiple phases of chemotherapy along with surgery or radiation therapy, followed by long-term follow-up.
What follow-up care is required after treatment?
Follow-up care includes regular clinical reviews, imaging, and functional assessment to monitor for recurrence, manage late effects, and support recovery and quality of life.
Does RGCIRC provide paediatric oncology services?
Yes. RGCIRC (Rajiv Gandhi Cancer Institute & Research Centre) provides specialised paediatric oncology services, including the diagnosis and treatment of childhood cancers such as Ewing’s sarcoma, supported by multidisciplinary teams and comprehensive supportive care.